Amendments to the claims:

Please cancel claims 1-13 without prejudice to their renewal in a related patent application.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-13. (Cancelled)

- 14. (currently amended) A non-human-animal <u>transgenic mouse</u> comprising an altered or deleted <u>endogenous</u> Calcium Independent Receptor of Latrotoxin 3–Like (CIRL3-L) gene, characterized by exhibiting anxiety-related <u>disorders</u>.
- 15. (currently amended) The non-human animal transgenic mouse of claim 16, characterized by exhibiting wherein the anxiety-related disorders[,] is one of obsessive-compulsive disorder (OCD)[,] or a perseverative developmental disabilitity (PDD), or compulsive behavior or related disorders.
- 16. (currently amended The non-human animal transgenic animal of claim 14 15, characterized by exhibiting wherein the anxiety-related disorder is PDD pervasive developmental disorders.

17. (cancelled)

- 18. (new) The transgenic mouse of claim 15, wherein the anxiety-related disorder is OCD.
- 19. (new) The transgenic mouse of claim 16, wherein the perserverative developmental disability is one of Asperger's Syndrome, autism, perserverative developmental disabilities not otherwise specified (PDD-NOS) or schizophrenia.
- 20. (new) The transgenic mouse of claim 14, further comprising a human CIRL3-L

USSN 10/804,532 Restriction Requirement dated 06 September2006 Response dated 10 October 2006

gene.

- 21. (new) The transgenic mouse of claim 20, wherein the anxiety-related disorders is one of obsessive-compulsive disorder (OCD) or a perserverative developmental disabilitity (PDD).
- 22. (new) The transgenic animal of claim 21, wherein the anxiety-related disorder is PDD.
- 23. (new) The transgenic mouse of claim 22, wherein the PDD is one of Asperger's Syndrome, autism, pervasive developmental disabilities not otherwise specified (PDD-NOS) or schizophrenia.
- 24. (new) The transgenic mouse of claim 20, wherein the anxiety-related disorder is OCD.
- 25. (new) A method of identifying an agent capable of reducing anxiety in a mammal, comprising administering a test agent to the animal of claim 14, and determining the ability of the test agent to reduce anxiety.
- 26. (new) A method of identifying an agent capable of reducing anxiety in a mammal, comprising administering a test agent to the animal of claim 20, and determining the ability of the test agent to reduce anxiety.